1800-272-662
Shopping Cart 0
countryflagAU
Login

Tryptamine Therapeutics Ltd

Healthcare AU TYP

NoneAUD
-(-%)

Last update at 2026-02-23T06:45:06.402524Z

Day Range

--
LowHigh

52 Week Range

0.030.05
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap54.72M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.09378M
  • Revenue TTM1.58M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM -0.81689M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -7.13026M -10.08401M -8.46805M -5.27880M -2.28287M
Minority interest - - - - -
Net income -7.13026M -10.16524M -8.46100M -5.21822M -2.19408M
Selling general administrative 6.41M 9.39M 7.90M 4.65M 1.36M
Selling and marketing expenses 0.09M 0.29M 0.33M 0.14M -
Gross profit -1.12349M -4.09109M 3.19M 2.23M -0.06001M
Reconciled depreciation 1.70M 1.73M 1.01M 0.38M -
Ebit -9.59156M -10.00279M -9.58942M -6.13152M -2.69408M
Ebitda -7.84950M -8.30135M -7.86099M -5.12515M -2.31166M
Depreciation and amortization 1.74M 1.70M 1.73M 1.01M 0.38M
Non operating income net other - - - - -
Operating income -6.79904M -10.00279M -12.66685M -8.00486M -2.37167M
Other operating expenses 10.21M 14.21M 12.67M 8.00M 2.37M
Interest expense 0.33M 0.08M - - -
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M -
Interest income 0.02M 0.00302M 0.00705M 0.06M -
Net interest income -0.31328M -0.07821M 0.00705M 0.06M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.08M -0.00705M -0.06058M -0.08880M
Total revenue 0.62M 0.10M 4.19M 2.62M -
Total operating expenses 10.21M 14.21M 12.67M 8.00M 2.37M
Cost of revenue 1.74M 4.19M 1.01M 0.38M 0.06M
Total other income expense net -0.31328M -0.07821M -0.05164M 2.73M 0.03M
Discontinued operations - - - - -
Net income from continuing ops -7.13026M -10.08401M -8.46805M -5.27880M -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 5.88M 13.61M 21.46M 6.54M 5.40M
Intangible assets 0.28M 0.33M 0.33M 0.33M 0.33M
Earning assets - - - - -
Other current assets 2.72M 4.17M 3.96M 2.11M 0.11M
Total liab 1.75M 4.81M 2.59M 1.53M 0.28M
Total stockholder equity 4.13M 8.81M 18.87M 5.02M 5.12M
Deferred long term liab - - - - -
Other current liab - - - - 0.14M
Common stock - - - - 7.58M
Capital stock 36.73M 34.31M 34.30M 12.76M -
Retained earnings -33.42062M -26.29036M -16.20635M -7.73830M -2.45923M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 1.64M 4.85M 12.72M 1.74M 4.42M
Cash and equivalents - - - - -
Total current liabilities 1.71M 4.46M 1.77M 0.92M 0.28M
Current deferred revenue - - - - -
Net debt - - - - -4.41896M
Short term debt - - - - -
Short long term debt 1.53M 2.75M - - -
Short long term debt total - - - - -
Other stockholder equity - - - - 0.00000M
Property plant equipment - - - - -
Total current assets 4.59M 9.46M 17.20M 4.06M 4.58M
Long term investments - - - 0.28M -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables - - - 0.02M 0.05M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.04M 0.21M 0.31M 0.14M 0.04M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - 0.00000M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.58M 0.45M 0.04M -0.81912M
Deferred long term asset charges - - - - -
Non current assets total 1.30M 4.15M 4.26M 2.48M 0.82M
Capital lease obligations - 1.00M 1.36M 0.91M -
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.27664M -1.23515M -1.79892M -0.94959M -
Change to liabilities - - - - -
Total cashflows from investing activities -0.27664M -1.23515M -1.79892M -0.94959M -0.85865M
Net borrowings - - - - -
Total cash from financing activities 0.92M 1.88M 20.61M 4.97M 7.41M
Change to operating activities - - - - -
Net income -7.13026M -10.16524M -8.46805M -5.27880M -2.28287M
Change in cash -3.20382M -7.87704M 10.98M -2.67604M 4.37M
Begin period cash flow 4.85M 12.72M 1.74M 4.42M 0.05M
End period cash flow 1.64M 4.85M 12.72M 1.74M 4.42M
Total cash from operating activities -3.84582M -8.43681M -7.82863M -6.71840M -2.18452M
Issuance of capital stock 1.57M - 22.00M 5.18M 7.41M
Depreciation 1.74M 1.73M 1.01M 0.38M 0.06M
Other cashflows from investing activities 0.00816M -0.10995M 0.01M -0.04000M -0.32500M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - -0.84000M - -
Other cashflows from financing activities 0.92M 1.88M 20.61M 4.97M 7.41M
Change to netincome - - - - -
Capital expenditures 0.28M 1.13M 1.63M 0.63M 0.86M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.70237M 6.60M 2.83M 0.29M 0.04M
Stock based compensation - 0.02M 0.72M - -
Other non cash items 3.24M 8.44M -2.31319M -2.11089M 0.05M
Free cash flow -4.13062M -9.56201M -9.45398M -7.35020M -3.04317M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TYP
Tryptamine Therapeutics Ltd		 - -% - - - 34.60 9.19 18.22 -0.2684
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin currently under phase 2a clinical trial for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia and irritable bowel syndrome. The company was formerly known as Tryptamine Therapeutics Limited and changed its name to Entropy Neurodynamics Limited in November 2025. Entropy Neurodynamics Limited was founded in 2019 and is based in Camberwell, Australia.

Tryptamine Therapeutics Ltd

697 Burke Road, Camberwell, VIC, Australia, 3124

Key Executives

Name Title Year Born
Dr. James P. Gilligan MSIB, Ph.D. President & Chief Scientific Officer 1952
Mr. Peter Molloy ASIP, B.A., C.F.A. Chief Business Officer & Executive Director 1972
Mr. Jason Carroll MD, CEO & Executive Director NA
Dr. William James Garner M.D., M.P.H., MPH Founder & MD 1966
Mr. Hamish George B.Com., C.A. Chief Financial Officer NA
Dr. James P. Gilligan MSIB, Ph.D. President & Chief Scientific Officer 1952
Mr. Peter Molloy ASIP, B.A., C.F.A. Chief Business Officer & Executive Director 1972
Mr. Jason Carroll MD, CEO & Executive Director NA
Dr. William James Garner M.D., M.P.H., MPH Founder & MD 1966
Mr. Hamish George B.Com., C.A. Chief Financial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.